Geovax Labs Inc
GOVX
Company Profile
Business description
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
Contact
1900 Lake Park Drive
Suite 380
SmyrnaGA30080
USAT: +1 678 384-7220
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
17
Stocks News & Analysis
video
Do you qualify as 'rich'?
Morningstar's Sim Mody speaks with Mark LaMonica about the varying definitions of rich.
stocks
Megatrend Investing: ASX players to capitalise on the clean energy transition
Find out how you can benefit from global megatrends.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,683.40 | 55.00 | 0.64% |
| CAC 40 | 7,883.61 | 22.79 | -0.29% |
| DAX 40 | 21,532.77 | 27.07 | 0.13% |
| Dow JONES (US) | 44,579.93 | 158.02 | 0.36% |
| FTSE 100 | 8,602.56 | 31.79 | 0.37% |
| HKSE | 20,597.09 | 192.87 | -0.93% |
| NASDAQ | 19,546.63 | 107.38 | -0.55% |
| Nikkei 225 | 38,831.48 | 33.11 | 0.09% |
| NZX 50 Index | 12,844.59 | 60.45 | -0.47% |
| S&P 500 | 6,026.38 | 11.50 | -0.19% |
| S&P/ASX 200 | 8,416.90 | 37.50 | 0.45% |
| SSE Composite Index | 3,229.49 | 21.11 | -0.65% |